US 12,268,378 B2
Apparatus and methods for sealing a vascular puncture
Andreas Mylonakis, Fremont, CA (US); Jacky Au-Yeung, Millbrae, CA (US); and Florencia Lim, Union City, CA (US)
Assigned to ACCESS CLOSURE, INC., Santa Clara, CA (US)
Filed by ACCESS CLOSURE, INC., Santa Clara, CA (US)
Filed on Jun. 8, 2021, as Appl. No. 17/341,765.
Application 17/341,765 is a continuation of application No. 16/656,251, filed on Oct. 17, 2019, granted, now 11,058,406.
Application 16/656,251 is a continuation of application No. 15/726,928, filed on Oct. 6, 2017, granted, now 10,456,124, issued on Oct. 29, 2019.
Application 15/726,928 is a continuation of application No. 14/276,989, filed on May 13, 2014, granted, now 9,820,728, issued on Nov. 21, 2017.
Application 14/276,989 is a continuation in part of application No. 13/354,278, filed on Jan. 19, 2012, granted, now 10,182,800, issued on Jan. 22, 2019.
Claims priority of provisional application 61/434,412, filed on Jan. 19, 2011.
Prior Publication US 2022/0125419 A1, Apr. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 17/00 (2006.01); A61L 24/00 (2006.01); A61L 24/02 (2006.01); A61L 24/04 (2006.01); B29C 70/76 (2006.01); C08L 71/02 (2006.01); A61B 17/22 (2006.01); A61B 90/90 (2016.01)
CPC A61B 17/0057 (2013.01) [A61L 24/0031 (2013.01); A61L 24/02 (2013.01); A61L 24/04 (2013.01); B29C 70/766 (2013.01); C08L 71/02 (2013.01); A61B 2017/00495 (2013.01); A61B 2017/00526 (2013.01); A61B 2017/00561 (2013.01); A61B 2017/0065 (2013.01); A61B 2017/00654 (2013.01); A61B 2017/00672 (2013.01); A61B 2017/00871 (2013.01); A61B 2017/00884 (2013.01); A61B 2017/00889 (2013.01); A61B 2017/00893 (2013.01); A61B 2017/00898 (2013.01); A61B 2017/00951 (2013.01); A61B 2017/22067 (2013.01); A61B 2017/22069 (2013.01); A61B 90/90 (2016.02)] 37 Claims
 
1. A sealant for sealing a puncture through tissue, comprising:
an elongate first section extending from a proximal end to a distal end, and a cross-section sized for delivery into a puncture through tissue; and
a second section fused to and extending from the distal end of the first section, the second section comprising PEG-precursors comprising PEG-ester and PEG-amine precursors in an equivalent ratio of active group sites of PEG-ester/PEG-amine of at least about one-to-one (1:1), at least some of the precursors remaining in an unreactive state until exposed to an aqueous physiological environment, whereupon the precursors undergo in-situ cross-linking with one another to provide adhesion to tissue adjacent the puncture.